Registry of patients with brain tumors treated with GammaTiles

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry study aims to evaluate the real-world clinical outcomes and patient-reported outcomes of patients with brain tumors who have undergone treatment with STaRT using GammaTiles. A total of 600 patients who have had maximum safe resection of their brain tumors will be enrolled, and data will be collected on various outcomes including local control, overall survival, quality of life, neurocognition, and adverse events over a period of five years. The study will benchmark the effectiveness and safety of this treatment approach against existing standard-of-care therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles.
2. Willing and able to provide informed consent and to participate in all evaluations.

Exclusion Criteria:

1. Inability to undergo pre-operative and post-operative imaging for disease and implant assessment.
2. Major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and/or interfere with follow ups.
3. Subjects who, in the investigator's opinion, are unable to understand the protocol or to give informed consent, have a history of poor cooperation, noncompliance with medical treatment, or difficulty in returning for follow up care. A legally authorized representative may provide consent if the potential subject lacks the capacity to provide consent themselves.

Where it's running

• HonorHeath Scottsdale Osborn Medical Center
  Phoenix, Arizona, United States Recruiting
• University of Arkansas Medical Center
  Little Rock, Arkansas, United States Recruiting
• Eden Medical Center
  Castro Valley, California, United States Recruiting
• UCSD Moores Cancer Center
  La Jolla, California, United States Recruiting
• MemorialCare Health System
  Laguna Hills, California, United States Recruiting
• Desert Regional Medical Center
  Palm Springs, California, United States Recruiting

+4 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Michael A. Garcia, MD, MS
• Email: mgarcia@gtmedtech.com
• Phone: (833) 662-0044

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Characterizing immune cells in malignant brain tumors

  This study is trying to understand how immune cells behave in people with malignant brain tumors by looking at their blood and tumor samples before and after surgery.

  Recruiting IRCCS San Raffaele · Milan, Milan · NCT05831631

• Combining capecitabine and temozolomide for newly diagnosed glioblastoma

  This study is testing if combining two cancer drugs, capecitabine and temozolomide, can help people with newly diagnosed glioblastoma live longer and feel better compared to using temozolomide alone.

  Recruiting Phase 1/2 Northwell Health · New York, New York · NCT03213002

• Targeting brain tumors with a specific drug infusion and re-irradiation

  This study is testing a new way to deliver a drug directly to brain tumors in patients with certain aggressive types of glioblastoma to see if it can improve treatment results.

  Recruiting Phase 2 Northwell Health · New York, New York · NCT02800486

• One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions

  A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT07883720

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.